Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer

被引：0
|
作者：
Xia Xu
Fei Deng
Mengmeng Lv
Binhui Ren
Wenwen Guo
Xiaoxiang Chen
机构：
[1] Department of Chemotherapy,
[2] Jiangsu Cancer Hospital,undefined
[3] Department of Gynecologic Oncology,undefined
[4] Jiangsu Cancer Hospital,undefined
[5] Department of Thoracic Oncology,undefined
[6] Jiangsu Cancer Hospital,undefined
[7] The Second Affiliated Hospital of Nanjing Medical University,undefined
来源：
Journal of Ovarian Research | / 9卷
关键词：
High grade serous ovarian cancer; CA-125; Ascites; Primary debulking surgery; Interval debulking surgery;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy
    Lee, J-Y.
    Paik, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [22] Impact of neoadjuvant chemotherapy duration on the survival of patients with advanced stage high-grade serous or endometrioid ovarian carcinoma
    Nasioudis, Dimitrios
    Ko, Emily
    Haggerty, Ashley
    Cory, Lori
    Giuntoli, Robert
    Kim, Sarah
    Simpkins, Fiona
    Morgan, Mark
    Latif, Nawar
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S183 - S184
  • [23] Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome
    Wang, Zhigang C.
    Birkbak, Nicolai Juul
    Culhane, Aedin C.
    Drapkin, Ronny
    Fatima, Aquila
    Tian, Ruiyang
    Schwede, Matthew
    Alsop, Kathryn
    Daniels, Kathryn E.
    Piao, Huiying
    Liu, Joyce
    Etemadmoghadam, Dariush
    Miron, Alexander
    Salvesen, Helga B.
    Mitchell, Gillian
    DeFazio, Anna
    Quackenbush, John
    Berkowitz, Ross S.
    Iglehart, J. Dirk
    Bowtell, David D. L.
    Matulonis, Ursula A.
    CLINICAL CANCER RESEARCH, 2012, 18 (20) : 5806 - 5815
  • [24] Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma
    Marchocki, Zibi
    Tone, Alicia
    Virtanen, Carl
    de Borja, Richard
    Clarke, Blaise
    Brown, Theodore
    May, Taymaa
    JOURNAL OF OVARIAN RESEARCH, 2022, 15 (01)
  • [25] Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma
    Zibi Marchocki
    Alicia Tone
    Carl Virtanen
    Richard de Borja
    Blaise Clarke
    Theodore Brown
    Taymaa May
    Journal of Ovarian Research, 15
  • [26] Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancer
    Elorbany, Samar
    Berlato, Chiara
    Carnevalli, Larissa S.
    Maniati, Eleni
    Barry, Simon T.
    Wang, Jun
    Manchanda, Ranjit
    Kzhyshkowska, Julia
    Balkwill, Frances
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [27] Toxicity and Therapy Outcome Associations in High-grade Serous Ovarian Cancer
    Deng, F.
    Laasik, M.
    Salminen, L.
    Lapatto, L.
    Huhtinen, K.
    Li, Y.
    Hautaniemi, S.
    Hynninen, J.
    Niemi, M.
    Lehtonen, R.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (SUPPL 1) : S96 - S96
  • [28] The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer
    van Baal, J. O. A. M.
    Van de Vijver, K. K.
    Algera, M. D.
    van Der Aa, M. A.
    Sonke, G. S.
    van Driel, W. J.
    Kenter, G. G.
    Amant, F. C.
    Lok, C. A. R.
    GYNECOLOGIC ONCOLOGY, 2019, 153 (03) : 562 - 567
  • [29] The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer
    van Baal, J.
    Van de Vijver, K.
    Algera, M.
    van der Aa, M.
    Sonke, G.
    van Driel, W.
    Kenter, G.
    Amant, F.
    Lok, C.
    VIRCHOWS ARCHIV, 2019, 475 : S88 - S88
  • [30] THE EFFECT OF ADJUVANT CHEMOTHERAPY ON SURVIVAL IN PATIENTS WITH FIGO STAGE I HIGH-GRADE SEROUS OVARIAN CANCER
    van Baal, J.
    Van de Vijver, K.
    van der Aa, M.
    Sonke, G.
    van Driel, W.
    Kenter, G.
    Amant, F.
    Lok, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 756 - 757
12345